These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 22140424

  • 21. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis.
    Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC.
    Value Health; 2004; 7(5):554-68. PubMed ID: 15367251
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.
    Lancet; 1998 Nov 07; 352(9139):1491-7. PubMed ID: 9820296
    [Abstract] [Full Text] [Related]

  • 24. Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b.
    Fitzgerald KC, Munger KL, Köchert K, Arnason BG, Comi G, Cook S, Goodin DS, Filippi M, Hartung HP, Jeffery DR, O'Connor P, Suarez G, Sandbrink R, Kappos L, Pohl C, Ascherio A.
    JAMA Neurol; 2015 Dec 07; 72(12):1458-65. PubMed ID: 26458124
    [Abstract] [Full Text] [Related]

  • 25. Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis.
    Arnason BG.
    J Neurol; 2005 Sep 07; 252 Suppl 3():iii28-iii33. PubMed ID: 16170497
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Network analysis of randomized controlled trials in multiple sclerosis.
    Zintzaras E, Doxani C, Mprotsis T, Schmid CH, Hadjigeorgiou GM.
    Clin Ther; 2012 Apr 07; 34(4):857-869.e9. PubMed ID: 22444787
    [Abstract] [Full Text] [Related]

  • 28. The Multiple Sclerosis Risk Sharing Scheme Monitoring Study--early results and lessons for the future.
    Pickin M, Cooper CL, Chater T, O'Hagan A, Abrams KR, Cooper NJ, Boggild M, Palace J, Ebers G, Chilcott JB, Tappenden P, Nicholl J.
    BMC Neurol; 2009 Jan 06; 9():1. PubMed ID: 19126193
    [Abstract] [Full Text] [Related]

  • 29. Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.
    Kopp TI, Blinkenberg M, Petersen T, Sorensen PS, Magyari M.
    Mult Scler Relat Disord; 2020 May 06; 40():101956. PubMed ID: 32007654
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Early treatment and dose optimisation BENEFIT and BEYOND.
    Hartung HP.
    J Neurol; 2005 Sep 06; 252 Suppl 3():iii44-iii50. PubMed ID: 16170501
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Randomized controlled trials to assess therapies for multiple sclerosis.
    Wingerchuk DM, Noseworthy JH.
    Neurology; 2002 Apr 23; 58(8 Suppl 4):S40-8. PubMed ID: 11971125
    [Abstract] [Full Text] [Related]

  • 34. Interferon beta for secondary progressive multiple sclerosis.
    La Mantia L, Vacchi L, Di Pietrantonj C, Ebers G, Rovaris M, Fredrikson S, Filippini G.
    Cochrane Database Syst Rev; 2012 Jan 18; 1(1):CD005181. PubMed ID: 22258960
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.
    Bielekova B, Howard T, Packer AN, Richert N, Blevins G, Ohayon J, Waldmann TA, McFarland HF, Martin R.
    Arch Neurol; 2009 Apr 18; 66(4):483-9. PubMed ID: 19364933
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Interferon-beta-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis.
    McCormack PL, Scott LJ.
    CNS Drugs; 2004 Apr 18; 18(8):521-46. PubMed ID: 15182221
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.